Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis (<scp>ADVISE</scp>)

Abstract

The primary outcome was not met, although efficacy was observed for etrasimod 2 mg on several clinician- and patient-assessed measures, and both 1- and 2-mg doses were well tolerated, warranting further clinical investigation in AD.